The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.
The U.S. Food and Drug Administration (FDA) on Friday approved Bristol Myers Squibb & Co.’s BMY Opdivo (nivolumab) with chemotherapy for untreated Hodgkin lymphoma, one of the most curable forms of ...
The FDA has approved the combination of nivolumab plus chemotherapy as first-line treatment for certain patients with stage III or IV classical Hodgkin lymphoma.The approval, for individuals aged 12 ...
The FDA has granted orphan drug designation (ODD) to a locally delivered formulation of irinotecan (ChemoSeed) for the ...
A phase 2 trial evaluated the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in patients with urothelial non-muscle invasive bladder cancer.
This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...
Pharmacosmos initiates phase III clinical trial of trilaciclib in limited-stage small cell lung cancer MORRISTOWN, NJ, ...
Olema Pharmaceuticals, Inc. ('Olema” or 'Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies ...
A DR5-mediated apoptotic strategy combined with irinotecan/temozolomide achieved a 64.5% ORR and 87.1% DCR in ...
Pharmaceutical companies are shifting from the development of autologous cell therapies to allogeneic cell therapies.
BriGene Biosciences supported Grit with technology transfer, manufacturing, and regulatory requirements for the IND for GT307.
Recommendation is based on peer-reviewed clinical data supporting long-term effectiveness and safety durability in patients with papillary-only disease treated with ANKTIVA plus BCG1.CULVER CITY, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results